Filing Flows › Health Care › Pacira BioSciences (PCRX)
Pacira BioSciences (PCRX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Pacira BioSciences (PCRX) Q3 2026 earnings results →
Q3 2026 Revenue down 2% year over year to $177M · 16¢ of every $1 of revenue kept as net profit · operating margin 12.6%
Pacira BioSciences made $177M in Q3 2026 (-2% Y/Y): Net product sales $175M, Bupivacaine liposome injectable suspension $1.2M. Operating margin 12.6%, net earnings $28.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $176.7M in Q3 2026, down 2% year over year and down 8% from the previous quarter. EXPAREL was the largest line at 81% of revenue. iovera° lost $4.5M year over year (down 69%), 157% of the total change.
Operating profit was $22.3M, a 12.6% margin (up 9.1 points year over year). Total costs fell 11% while revenue fell 2%. Net earnings were $28.5M, up 425% year over year. The effective tax rate was 1.0%. Non-operating items added $6.5M, 23% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $50.1M (down 18% year over year), 176% of net earnings. Non-cash charges added back $19.3M of depreciation and amortization and $11.8M of share-based compensation. Working capital and other items used $9.5M. Capital expenditures of $3.6M left free cash flow of $46.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $177M | -2% | 12.6% | $28.5M | $50.1M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $192M | +6% | 2.2% | $4.7M | $57.5M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $177M | +5% | 3.9% | $2.9M | $25.7M |
| Q4 2025 | 10-K | Feb 26, 2026 | $197M | +5% | 1.2% | $1.6M | $43.7M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $180M | +6% | 3.5% | $5.4M | $60.8M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $181M | +2% | 4.7% | −$4.8M | $12.0M |
| Q1 2025 | 10-Q | May 8, 2025 | $169M | +1% | 1.2% | $4.8M | $35.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- MCK — 31% of its revenue · Stated in 10-K (sentence) · source
- CAH — 26% of its revenue · Stated in 10-K (sentence) · source
- COR — 22% of its revenue · Stated in 10-K (sentence) · source
About Pacira BioSciences
Pacira BioSciences, Inc., a Delaware corporation, is the holding company for our California operating subsidiary named Pacira Pharmaceuticals, Inc. In March 2007, we acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.), or Skyepharma (the “Skyepharma Acquisition”). In April 2019, we acquired MyoScience, Inc., a privately held medical technology company (the “MyoScience Acquisition”), in November 2021, we acquired Flexion Therapeutics, Inc., or Flexion, a publicly traded biopharmaceutical company (the “Flexion Acquisition”) and in February 2025, we acquired GQ Bio Therapeutics GmbH, or GQ Bio, a privately-held biopharmaceutical company (the “GQ Bio Acquisition”).
In its own words, from its 10-K, filed Feb 26, 2026.
Pacira BioSciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -2% against the peers' median +7%. Operating margin: 12.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PCRX Pacira BioSciences | Q3 2026 | $177M | -2% | 12.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Pacira BioSciences 10-Q on SEC EDGAR · CIK 1396814 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns PCRX and who is buying
More on PCRX
- How Pacira BioSciences makes money: revenue by segment
- Pacira BioSciences stock forecast, price target and fair value
- Who owns Pacira BioSciences stock: holders, funds and Congress trades
- Pacira BioSciences guidance and outlook
- Is Pacira BioSciences a takeover target? LBO and rumors
- Pacira BioSciences recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Pacira BioSciences operating margin by quarter
- Pacira BioSciences net income by quarter
- Pacira BioSciences free cash flow by quarter
- Pacira BioSciences R&D spending by quarter
- Pacira BioSciences capital expenditures by quarter
- Pacira BioSciences Net product sales revenue by quarter
- Pacira BioSciences Bupivacaine liposome injectable suspension revenue by quarter